Notably, siXIAP-treated mice exhibited higher glucose levels and dramatic shifts in area under curve (AUC) scores, suggesting that knockdown of XIAP in vivo may impair glucose tolerance and insulin sensitivity, further exacerbating metabolic disorders. Here, INS is linked to metabolic disease.